• Cubist Pharmaceuticals Inc., of Lexington, Mass., reported second-quarter revenues of $230.6 million, and earnings per share of 58 cents, solidly beating analyst estimates of 45 cents per share. The company reported net revenues of $212 million for antibiotic Cubicin (daptomycin), an increase of 20 percent over the second quarter of 2011.